YPSOMED SELFCARE SOLUTIONS - Key Persons

Job Titles:

• Member of the Board of Directors
• Member of the Board of Directors of Ypsomed Holding AG
• Unaran - Member

After graduating from Bogazici University with a degree in industrial engineering, she started her career working in several positions at Procter & Gamble in Istanbul and Frankfurt. Following her MBA at INSEAD, she joined McKinsey & Company as a consultant in 2004 and worked in London and Geneva offices in different industries with a focus on healthcare, strategy and transformation. From 2012-2017 she worked at Ferring Pharmaceuticals where she acted first as Director of Global Operations and then as Global Head of Digital. She continued to be Global Head of Digital Medicines at Novartis Pharmaceuticals and member of the Global Commercial Leadership Team of Novartis Pharma as well as Global Digital Leadership Team of Novartis from 2018-2019. She currently works as Chief Strategy and Digital Officer at Zur Rose Group AG, the biggest e-commerce pharmacy in Europe, where she is responsible for the group strategy and realizing the digital vision of the group to become the healthcare ecosystem of Europe. She was also a member of the Advisory Board of NATIVE in 2020, a leading design agency in London and San Francisco. She is also a member of the Advisory Board of Lumanity, an Arsenal Capital Partners company with a vision to accelerate and optimise access to medical advances.

Job Titles:

• Member of the Board of Directors
• Member of the Board of Directors of Ariceum Therapeutics
• Member of the Board of Directors of Ypsomed Holding AG

Martin Münchbach is currently a member of the Board of Directors of Ariceum Therapeutics in Munich, Germany, Alentis Therapeutics AG in Basel, Binx Health Ltd. in Trowbridge, UK and River Renal Inc. in New York USA.

Eli Lilly is focusing on its successful drug portfolio and is halting its ambition to enter insulin pump business. Ypsomed remains committed to its US YpsoPump ambitions with a new partner. Read more … Eli Lilly is focusing on its successful drug portfolio and is halting its ambition to enter insulin pump business. Ypsomed remains committed to its US YpsoPump ambitions with a new partner.

Job Titles:

• Chief Operations Officer
• COO

Job Titles:

• Chairman of the Board of Directors
• Member of the Board of Directors of Ypsomed Holding AG

After completing his banking apprenticeship at the Bankverein and HWV in St. Gallen, he worked from 1988 to 1998, at UBS in investment banking in Switzerland and abroad. In 1998 he moved to the MedTech industry as CFO at Straumann, where he was appointed CEO in 2002 and Chairman of the Board of Directors of Straumann Holding AG in 2010. In this function, he has been a member of the Board of Directors of the academic partner organisation ITI (International Team for Team for Implantology). In addition, Gilbert Achermann was Chairman of the Board of Directors of Siegfried Holding AG in Zofingen and of Vitra Holding AG in Birsfelden. Since 2012, he is a member of the Board of Directors of the Private Bank Julius Baer, since 2016, a committee member of the Chamber of Commerce of both Basle cantons, since 2016, a member of the Supervisory Board of the IMD in Lausanne and, since 2020, a member of the Board of Swiss Medtech. In addition, he is a jury member of Venture Kick and an active investor in Swiss start-ups.

Job Titles:

• Member of the Board of Directors
• Member of the Board of Directors of Ypsomed Holding AG

After graduating from Brussels University with a degree in chemical engineering and an MBA from Carnegie Mellon University in Pittsburgh, he held various positions at Abbott Laboratories Inc. and Merck and Co. Inc. He joined the Boehringer Ingelheim Group in 2003. For the first five years, he headed the Human Pharmaceuticals Division in the USA. From 2008 to 2011, he lived in Germany to lead the worldwide marketing team for human pharmaceuticals. During his tenure at the Boehringer Ingelheim Group, the company experienced strong sales, profit and profitability growth in the USA. From 2012 to 2018, he was Chairman of the Board of Directors and CEO of Boehringer Ingelheim USA as well as Country Managing Director for the United States. Paul Fonteyne previously served as Chairman of the National Pharmaceutical Council (NPC), and was a member of the board of Pharmaceutical Research and Manufacturers of America (PhRMA), as well as ResTORbio Inc. (until 2020) and AMAG Pharmaceuticals Inc. (until 2020). He is currently a member of the Board of Directors of Covetrus Inc. (since 2021) and of four biotechnology companies Amylyx Pharmaceuticals Inc., Gelesis Inc. and Appelis Pharmaceutical Inc., all based in Boston, and Dal- Cor Inc., based in London.

Job Titles:

• Chief Business Officer ( CBO ) YDS